Kyntra Bio (NASDAQ:KYNB) Releases Quarterly Earnings Results, Misses Expectations By $0.38 EPS

Kyntra Bio (NASDAQ:KYNB) posted its quarterly earnings data on Monday. The company reported ($3.74) earnings per share for the quarter, missing the consensus estimate of ($3.36) by ($0.38), Zacks reports.

Kyntra Bio Stock Performance

Shares of Kyntra Bio stock traded down $0.15 during midday trading on Monday, hitting $6.80. 15,619 shares of the company were exchanged, compared to its average volume of 26,389. The company has a market capitalization of $27.54 million, a price-to-earnings ratio of 0.15 and a beta of 1.03. Kyntra Bio has a 52 week low of $4.85 and a 52 week high of $12.60. The firm has a 50 day simple moving average of $7.04.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on KYNB shares. HC Wainwright raised Kyntra Bio to a “strong-buy” rating in a research report on Friday, February 27th. Wall Street Zen raised Kyntra Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Weiss Ratings started coverage on Kyntra Bio in a report on Wednesday, January 14th. They set a “sell (d+)” rating on the stock. Finally, Zacks Research lowered Kyntra Bio from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.